生物制药公司Nuvig Therapeutics获得1.61亿美元，为更好地治疗自身免疫性疾病奠定基础-动脉网

Nuvig Therapeutics Nabs $161M to Build Case for a Better Approach to Autoimmune Disease

MedCity News 等信源发布 2024-12-06 02:08



可切换为仅中文







Standard treatment for many autoimmune diseases includes drugs that suppress the immune system. Even when this approach works (and it doesn’t work for everyone), chronic immunosuppression puts patients at risk of infections among other complications. Nuvig Therapeutics is developing a first-in-class drug that could offer an alternative treatment for autoimmune diseases and the startup now has $161 million to advance clinical development of its lead program..

许多自身免疫性疾病的标准治疗方法包括抑制免疫系统的药物。即使这种方法有效（并非对所有人都有效），慢性免疫抑制也会使患者面临感染风险和其他并发症。Nuvig Therapeutics正在开发一种一流的药物，可以为自身免疫性疾病提供替代治疗，这家初创公司目前拥有1.61亿美元，用于推进其领先项目的临床开发。。

Nuvig aims to treat autoimmune disease by tapping into a built-in mechanism of the body that tamps down inflammatory pathways. The Menlo Park, California-based company’s drugs are proteins engineered to bind to type II Fc receptors, a class of receptors that regulate immune responses. The company says the binding of its drug to these receptors leads to the expansion of regulatory T cells, or Tregs, a type of immune cell that suppresses immune responses.

Nuvig旨在通过利用体内抑制炎症途径的内在机制来治疗自身免疫性疾病。这家位于加利福尼亚州门洛帕克的公司的药物是经过工程改造的蛋白质，可与II型Fc受体结合，II型Fc受体是一类调节免疫反应的受体。该公司表示，其药物与这些受体的结合会导致调节性T细胞（Tregs）的扩增，Tregs是一种抑制免疫反应的免疫细胞。

This approach also downregulates numerous inflammatory pathways ..

这种方法还下调了许多炎症途径。。

Lead Nuvig program NVG-2089 has Phase 1 results showing it was safe and well tolerated. Also important, the results showed the drug engaged its target. In Phase 2, Nuvig will test NVG-2089 as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), a rare disorder in which the immune system attacks myelin, the protective sheath covering nerve fibers.

领导Nuvig计划NVG-2089的第一阶段结果表明它是安全且耐受性良好的。同样重要的是，结果显示该药物达到了其目标。在第二阶段，Nuvig将测试NVG-2089作为慢性炎症性脱髓鞘性多发性神经病（CIDP）的治疗方法，CIDP是一种罕见的疾病，免疫系统会攻击髓鞘（覆盖神经纤维的保护鞘）。

This disease leads to nerve and motor problems as well as progressively worsening muscle function..

这种疾病会导致神经和运动问题，并逐渐恶化肌肉功能。。

Exclusive

独家

Heard at HLTH 2024: Insights from Innovative Healthcare Executives

在HLTH 2024上听到：来自创新医疗保健高管的见解

Executives from Imagine360, Verily, BrightInsight, Lantern, and Rhapsody shared their approaches to reducing healthcare costs and facilitating digital transformation.

来自Imagine360、Verily、BrightInsight、Lantern和Rhapsody的高管分享了他们降低医疗成本和促进数字转型的方法。

By MedCity News

By√9；：<9MedCity News

Standard CIDP treatment includes intravenous immunoglobulin (IVIg), an infusion of antibodies sourced from healthy donors. This treatment provides a patient with antibodies that block the inflammatory processes that damage myelin. Immunosuppressants are another CIDP treatment option. Not all patients respond to these therapies, but there’s already a new alternative.

标准的CIDP治疗包括静脉注射免疫球蛋白（IVIg），这是一种来自健康供体的抗体输注。这种治疗方法为患者提供了阻断破坏髓鞘的炎症过程的抗体。免疫抑制剂是另一种CIDP治疗选择。并非所有患者都对这些疗法有反应，但已经有了新的替代方法。

This past June, the FDA expanded the approval of Argenx drug Vyvgart Hytrulo to include CIDP. This injectable drug, which was initially approved to treat generalized myasthenia gravis, is an antibody fragment designed to bind to and block the neonatal Fc receptor (FcRn). Consequently, disease-driving autoantibodies go to a cellular system that degrades proteins..

今年6月，FDA扩大了对阿根克斯药物Vyvgart Hytrulo的批准范围，将CIDP包括在内。这种最初被批准用于治疗全身性重症肌无力的可注射药物是一种抗体片段，旨在结合并阻断新生儿Fc受体（FcRn）。因此，驱动疾病的自身抗体进入降解蛋白质的细胞系统。。

Through the first three quarters of 2024, Argenx reported more than $1.4 billion in product sales, a 77.5% increase over the same period in 2023. These figures includes Vyvgart, the original intravenously infused formulation of the FcRn inhibitor. Argenx has touted its drug’s potential uses in a wide range of autoimmune indications and the company is in various stages of clinical development testing its FcRn-blocker in multiple diseases.

2024年前三个季度，阿根克斯的产品销售额超过14亿美元，比2023年同期增长77.5%。这些数字包括Vyvgart，FcRn抑制剂的原始静脉输注制剂。Argenx吹嘘其药物在广泛的自身免疫适应症中的潜在用途，该公司正在临床开发的各个阶段测试其FcRn阻滞剂在多种疾病中的应用。

Similarly, Nuvig says its drug has the potential to address many autoimmune indications. But first, the company will see how its drug works in CIDP..

同样，Nuvig表示，其药物有可能解决许多自身免疫适应症。但首先，该公司将了解其药物在CIDP中的作用。。

Nuvig chose CIDP because it is an indication where IVIg is the standard of care and there is still unmet need for a better-tolerated therapy that is not immunosuppressive, co-founder and Chief Scientific Officer Pamela Conley said in an email. She added that her company’s approach is distinct from that of the Argenx drug and other FcRn inhibitors.

联合创始人兼首席科学官帕梅拉·康利（PamelaConley）在一封电子邮件中表示，Nuvig之所以选择CIDP，是因为它表明IVIg是治疗的标准，而且对更好的非免疫抑制耐受性治疗的需求仍未得到满足。她补充说，她的公司的方法不同于Argenx药物和其他FcRn抑制剂。

Most autoimmune diseases, including CIDP, are not entirely mediated by the presence of autoantibodies, she explained. Rather, most of the damage in CIDP is mediated by immune cells that infiltrate the myelin that protect nerve cells..

她解释说，包括CIDP在内的大多数自身免疫性疾病并不完全由自身抗体的存在介导。相反，CIDP中的大多数损伤是由免疫细胞介导的，免疫细胞浸润髓鞘以保护神经细胞。。

An FcRn blocker like Argenx’s drug does nothing to reduce the infiltration of immune cells into myelin, Conley said. Furthermore, blocking FcRn leads to an up to 80% reduction in overall circulating antibodies. Chronic maintenance of these low antibody levels is immunosuppressive, putting patients at risk of infection..

Conley说，像Argenx的药物这样的FcRn阻滞剂对减少免疫细胞向髓鞘的浸润没有任何作用。此外，阻断FcRn导致整体循环抗体减少高达80%。长期维持这些低抗体水平是免疫抑制性的，使患者处于感染风险中。。

Sponsored Post

赞助帖子

The Funding Model for Cancer Innovation is Broken — We Can Fix It

癌症创新的资助模式被打破了-我们可以修复它

Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.

缩小癌症健康公平差距需要通过新的资助方法实现医学突破。

By Eve McDavid - CEO of Mission-Driven Tech

作者Eve McDavid，任务驱动技术公司首席执行官

Rather than being immunosuppressive, Nuvig’s drug is immunomodulatory, Conley said. The drug offers a broader approach by down regulating the response of immune cells that drive inflammation while also expanding and activating Tregs, which is similar to what happens with IVIg. Conley added that clinical tests of the Argenx drug showed the overall response of CIDP patients was less than what has been observed in CIDP studies with IVIg..

康利说，Nuvig的药物不具有免疫抑制作用，而是具有免疫调节作用。该药物提供了一种更广泛的方法，通过下调驱动炎症的免疫细胞的反应，同时扩大和激活Tregs，这与IVIg相似。康利补充说，阿根克斯药物的临床试验表明，CIDP患者的总体反应低于IVIg在CIDP研究中观察到的反应。。

“We believe that the [mechanism of action] of NVG-2089 will lead to greater efficacy in CIDP than what was observed with Vyvgart,” Conley said.

康利说：“我们相信NVG-2089的[作用机制]将比Vyvgart观察到的更有效地治疗CIDP。”。

Nuvig, which is based on research from The Rockefeller University, emerged from stealth in 2022 backed by a $47 million Series A round. The new Series B round was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture Partners. Other participants include new investors B Capital, Leaps by Bayer, Global BioAccess Fund, LOTTE Holdings, Alexandria Venture Investments, and funds managed by abrdn Inc., as well as earlier investors Novo Holdings, Platanus, Bristol Myers Squibb, Digitalis Ventures, and Mission BioCapital..

Nuvig基于洛克菲勒大学的研究，于2022年在4700万美元的首轮融资支持下从隐形中脱颖而出。新的B轮由赛诺菲风险投资公司、蓝猫头鹰医疗保健机会公司（前身为Cowen Healthcare Investments）和Norwest Venture Partners共同领导。其他参与者包括new investors B Capital、Leaps by Bayer、Global BioAccess Fund、LOTTE Holdings、Alexandria Venture Investments和abrdn Inc.管理的基金，以及早期投资者Novo Holdings、Platanus、Bristol-Myers Squibb、Digitalis Ventures和Mission BioCapital。。

Here’s a recap of other recent biotech financing news:

以下是最近其他生物技术融资新闻的概述：

—Metabolic medications biotech Antag Therapeutics raised €80 million (about $80.6 million) to enter the clinic with obesity drug candidate AT-7687, a peptide designed to block the GIP receptor. The drug is based on an endogenous GIP receptor antagonist. The drug is intended to be dosed alongside current or future obesity drugs, including those that block the GLP-1 receptor.

-代谢药物biotech Antag Therapeutics筹集了8000万欧元（约8060万美元），与肥胖候选药物AT-7687一起进入诊所，AT-7687是一种旨在阻断GIP受体的肽。该药物基于内源性GIP受体拮抗剂。该药物旨在与当前或未来的肥胖药物一起服用，包括那些阻断GLP-1受体的药物。

Compared to other drugs being developed to block GIP, Antag says its approach offers flexibility in dosing that could improve both efficacy and tolerability. The drug could also be used by itself as a maintenance treatment..

与其他正在开发的阻断GIP的药物相比，Antag说，它的方法在剂量上提供了灵活性，可以提高疗效和耐受性。这种药物也可以单独用作维持治疗。。

In tests in monkeys, Antag said AT-7687 dosed with a GLP-1 drug produced “best-in-industry weight loss” along with improved glycemic control and lipid profiles that were independent of weight changes. Antag added that these benefits were achieved without gastrointestinal side effects. The biotech’s pipeline includes drug combinations for other targets and a follow-on molecule that could offer monthly dosing.

在猴子的测试中，Antag说，服用GLP-1药物的AT-7687可以“实现行业最佳的体重减轻”，同时改善血糖控制和血脂水平，而与体重变化无关。Antag补充说，这些益处是在没有胃肠道副作用的情况下实现的。该生物技术公司的管道包括用于其他目标的药物组合和可以提供每月剂量的后续分子。

Versant Ventures led Antag’s Series A financing..

Versant Ventures领导了Antag的A系列融资。。

—Maze Therapeutics raised $115 million to advance clinical development of its two lead programs. MZE829, an oral drug designed to block a protein called APOL1, is on track to Phase 2 testing in the rare kidney disease focal segmental glomerulosclerosis. MZE782, an oral inhibitor of SCL6A19, is on in Phase 1 testing; South San Francisco-based Maze plans to evaluate it in chronic kidney disease and phenylketonuria.

-Maze Therapeutics筹集了1.15亿美元，以推进其两个领先项目的临床开发。MZE829是一种口服药物，旨在阻断一种名为APOL1的蛋白质，目前正在进行罕见肾脏疾病局灶性节段性肾小球硬化的2期测试。口服SCL6A19抑制剂MZE782正在进行第一阶段测试；位于旧金山南部的梅兹计划对其在慢性肾病和苯丙酮尿症中的作用进行评估。

Maze’s Series D round was co-led by Frazier Life Sciences and Deep Track Capital..

梅兹的D系列赛由弗雷泽生命科学公司和Deep Track Capital共同领导。。

—Adcendo, a developer of antibody drug conjugates for cancer, recently received FDA clearance to begin a Phase 1/2 test of ADCE-D01 in patients with advanced soft tissue sarcoma. Now it has $135 million to fund the clinical research. ADCE-D01 is designed to target uPARAP, a receptor that’s overexpressed in mesenchymal cancers, including subtypes of soft tissue sarcoma.

-Adcendo是癌症抗体-药物偶联物的开发人员，最近获得FDA批准，开始对晚期软组织肉瘤患者进行ADCE-D01的1/2期测试。现在它有1.35亿美元用于资助临床研究。ADCE-D01旨在靶向uPARAP，一种在间充质癌（包括软组织肉瘤亚型）中过表达的受体。

Copenhagen-based Adcendo earlier this year expanded its Series A round of funding to €98 million (about $102.5 million). The new round, a Series B financing, was led by TCGX..

总部位于哥本哈根的Adcendo今年早些时候将其A轮融资规模扩大到9800万欧元（约1.025亿美元）。新一轮B轮融资由TCGX牵头。。

—Kanglin Biotechnology unveiled $20 million in Series A financing to advance to clinical development with lead program, KL003, a gene therapy for the rare blood diseases beta thalassemia and sickle cell disease. Those diseases are already addressed by FDA-approved gene therapies from Vertex Pharmaceuticals and Bluebird Bio.

-康林生物技术（Kanglin Biotechnology）在A系列融资中公布了2000万美元，以推进临床开发，该项目是一项针对罕见血液病β地中海贫血和镰状细胞病的基因疗法。Vertex Pharmaceuticals和Bluebird Bio的FDA批准的基因疗法已经解决了这些疾病。

Hangzhou, China-based Kanglin claims its lentiviral vector-based therapy can be best in class with shorter time to transfusion independence and engraftment of the genetically modified cells. No investor details were disclosed..

总部位于中国杭州的康林声称，其基于慢病毒载体的疗法可以是同类中最好的，并且可以缩短输血独立性和转基因细胞植入的时间。没有披露投资者的详细信息。。

—35Pharma raised $53 million to support clinical development of HS135 for pulmonary hypertension and HS235 for cardiometabolic disease and obesity. Both drugs are fusion proteins designed to block activins and growth differentiation factors (GDFs), proteins associated with many diseases. Frazier Life Sciences led the Series C round for Montreal-based 35Pharma..

-35Pharma筹集了5300万美元，用于支持HS135治疗肺动脉高压和HS235治疗心脏代谢疾病和肥胖症的临床开发。这两种药物都是融合蛋白，旨在阻断激活素和生长分化因子（GDF），这两种蛋白质与许多疾病有关。弗雷泽生命科学公司（Frazier Life Sciences）领导了总部位于蒙特利尔的35Pharma公司的C轮系列赛。。

—Startup Valora Therapeutics emerged with $30 million to advance the development of a new class of drugs it calls antibody lectin chimera, or AbLecs. These engineered antibodies target the glycol-immune checkpoint, blocking glycans, sugar molecules on the surface of cells, from interacting with lectins.

-初创公司Valora Therapeutics斥资3000万美元，用于推进一类新药物的开发，该药物被称为抗体凝集素嵌合体（Abody凝集素chimera，简称AbLecs）。这些工程抗体靶向乙二醇免疫检查点，阻断细胞表面的聚糖和糖分子与凝集素的相互作用。

This approach has potential applications to cancer and autoimmune disease. Avalon BioVentures co-led the seed round of San Diego-based Valora..

这种方法在癌症和自身免疫性疾病中具有潜在的应用。阿瓦隆生物风险投资公司（AvalonBioventures）共同领导了位于圣地亚哥的瓦洛拉（Valora）的种子轮。。

—Enveda raised $130 million to support its pipeline of 10 programs and multiple discovery candidates, all from an AI technology platform that applies machine learning techniques to metabolomics data. In October, the Boulder, Colorado-based company began a Phase 1 study of ENV-294, a potential oral anti-inflammatory drug for atopic dermatitis and other inflammatory disorders.

-Enveda筹集了1.3亿美元，用于支持其10个项目和多个发现候选人的管道，所有这些都来自将机器学习技术应用于代谢组学数据的AI技术平台。10月，这家总部位于科罗拉多州博尔德的公司开始了ENV-294的第一阶段研究，ENV-294是一种治疗特应性皮炎和其他炎症性疾病的潜在口服抗炎药。

Kinnevik and FPV led the Series C round, which brings the company’s funding total to $360 million..

Kinnevik和FPV领导了C轮，使公司的资金总额达到3.6亿美元。。

—TRexBio closed $84 million to advance its lead internal program, TRB-061, through early clinical development. The drug is an agonist of the TNFR2 receptor, which is abundant on regulatory T cells in the skin and gut. TRB-061 is a potential treatment for atopic dermatitis and ulcerative colitis; a Phase 1 study is on track to begin in the first half of 2025.

-TRexBio通过早期临床开发，完成了8400万美元的资金，以推进其领先的内部项目TRB-061。该药物是TNFR2受体的激动剂，TNFR2受体在皮肤和肠道的调节性T细胞中含量丰富。TRB-061是特应性皮炎和溃疡性结肠炎的潜在治疗方法；第一阶段的研究预计将于2025年上半年开始。

Delos Capital led TRexBio’s Series B financing..

Delos Capital领导TRexBio的B系列融资。。

—Wellington Management and Venrock led the $215 million financing of Metsera, a clinical-stage developer of metabolic disorder drugs. The Series B round comes seven months after Metsera launched backed by $290 million. The most advanced program of the New York-based company is a long-acting GLP-1 drug administered once-monthly — a key dosing edge over currently available GLP-1 drugs that patients must inject once weekly.

-惠灵顿管理层和文洛克领导了Metsera的2.15亿美元融资，Metsera是代谢紊乱药物的临床阶段开发商。在梅瑟拉（Metsera）以2.9亿美元启动B轮融资七个月之后。这家总部位于纽约的公司最先进的项目是一种长效GLP-1药物，每月给药一次，这是目前可用的GLP-1药物的关键剂量优势，患者必须每周注射一次。

Metsera expects to report preliminary Phase 2 data in the first half of 2025..

梅瑟拉预计将在2025年上半年报告初步的第二阶段数据。。

—Alentis Therapeutics raised $181.4 million for clinical development of two antibody drug conjugates. ALE.P02 is on track to begin Phase 1/2 testing in advanced CLDN1-positive squamous solid tumors. ALE.P03 is being readied to enter the clinic in patients with CLDN-positive tumors. Alentis last raised money in 2023, a $103 million Series C round.

-Alentis Therapeutics为两种抗体-药物偶联物的临床开发筹集了1.814亿美元。啤酒。P02有望在晚期CLDN1阳性鳞状实体瘤中开始1/2期检测。啤酒。P03已准备好进入CLDN阳性肿瘤患者的诊所。阿伦蒂斯上一次筹集资金是在2023年，即C轮融资1.03亿美元。

Orbimed led the latest round, a Series D financing, along with co-leads Novo Holdings and Jeito Capital..

Orbimed与Novo Holdings和Jeito Capital共同领导了最新一轮的D系列融资。。

—Arda Therapeutics raised $43 million to take a new approach to treating chronic disease. Rather than modulating the activity of proteins produced by cells that drive disease, San Francisco-based Arda is developing targeted biologic drugs that deplete those cells. Andreessen Horowitz led Arda’s Series A financing..

-Arda Therapeutics筹集了4300万美元，以采取一种治疗慢性病的新方法。总部位于旧金山的Arda正在开发能够消耗这些细胞的靶向生物药物，而不是调节驱动疾病的细胞产生的蛋白质的活性。安德烈森·霍洛维茨（AndreessenHorowitz）领导了Arda的A系列融资。。

—Evommune raised $115 million as the biotech prepares for upcoming data readouts for two skin disease drugs. Lead program EVO756 is on expected to report data in the first half of 2025 from a Phase 2 test in chronic inducible urticaria. Phase 2 tests are also planned for EVO756 in chronic spontaneous urticaria and for EVO301 in atopic dermatitis.

-Evommune筹集了1.15亿美元，为即将公布的两种皮肤病药物的数据做准备。预计领先项目EVO756将在2025年上半年报告慢性诱发性荨麻疹的第二阶段测试数据。还计划对慢性自发性荨麻疹的EVO756和特应性皮炎的EVO301进行第二阶段测试。

Data from these tests are expected in 2026. RA Capital Management and Sectoral Asset Management led the Palo Alto-based biotech’s Series C financing..

预计2026年将获得这些测试的数据。RA资本管理和部门资产管理领导了总部位于帕洛阿尔托的生物技术公司的C系列融资。。

—Trace Neuroscience launched with $101 million and a lead program in development for amyotrophic lateral sclerosis (ALS). The South San Francisco-based biotech says its antisense oligonucleotide drug restore a protein called UNC13A, which in turn reestablishes healthy communication between nerves and muscle cells that are affected by neurodegenerative disorders.

-Trace Neuroscience以1.01亿美元的资金启动了肌萎缩侧索硬化症（ALS）开发的领先项目。总部位于南旧金山的生物技术公司表示，其反义寡核苷酸药物可以恢复一种叫做UNC13A的蛋白质，而UNC13A又可以恢复受神经退行性疾病影响的神经和肌肉细胞之间的健康通讯。

Third Rock Ventures led Trace’s Series A financing..

Third Rock Ventures领导Trace的A系列融资。。

—Axonis Therapeutics has $115 million to support a lead program in development for treating epilepsy and pain. The Boston-based company’s drug candidate, AXN-027, targets KCC2, a chloride transporter in the central nervous system that is essential for inhibitory neurotransmission. It’s the same target being pursued by Ovid Therapeutics, which acquired its KCC2-targeting molecules from AstraZeneca.

-Axonis Therapeutics拥有1.15亿美元，用于支持开发用于治疗癫痫和疼痛的领先项目。这家总部位于波士顿的公司的候选药物AXN-027靶向KCC2，KCC2是中枢神经系统中的一种氯化物转运蛋白，对抑制性神经传递至关重要。这与Ovid Therapeutics追求的目标相同，Ovid Therapeutics从阿斯利康获得了KCC2靶向分子。

Cormorant Asset Management and venBio Partners co-led Axonis’s Series A financing..

Cormorant Asset Management和venBio Partners共同领导Axonis的A系列融资。。

—Blue Earth Therapeutics announced its presence in the growing radiopharmaceuticals sector with a $76.5 million Series A round. The Oxford, U.K.-based company will apply the proceeds toward Phase 2 tests of its radioligand therapies that target PSMA, the same protein hit by Novartis radiopharmaceutical Pluvicto.

-Blue Earth Therapeutics宣布其以7650万美元的a轮系列收入进入不断增长的放射性药物领域。这家总部位于英国牛津的公司将把所得资金用于针对PSMA的放射性配体疗法的第二阶段测试，PSMA是诺华放射性药物Pluvicto生产的同一种蛋白质。

Soleus Capital led the round, which was co-led by Sands Capital Management..

比目鱼资本（Soleus Capital）领跑了由金沙资本管理（Sands Capital Management）共同领衔的这一轮。。

—Archon Biosciences, a Seattle startup from the University of Washington lab of Nobel Prize-winning scientist David Baker, emerged with $20 million and a platform technology that designs antibodies in a way that controls their structure. These antibody cages, or AbCs, can control how a drug distributes in the body to potentially offer advantages in safety and potency.

-Archon Biosciences是华盛顿大学诺贝尔奖获得者David Baker实验室在西雅图成立的一家初创公司，拥有2000万美元的资金和一项平台技术，该技术以控制抗体结构的方式设计抗体。这些抗体笼或ABC可以控制药物在体内的分布，从而可能在安全性和效力方面提供优势。

Madrona Ventures led Archon’s seed financing..

Madrona Ventures领导Archon的种子融资。。

—Kivu Bioscience launched with $92 million, revealing antibody drug conjugates and technology licensed from Lonza subsidiary Synaffix. The startup, named for Lake Kivu in Africa, isn’t disclosing its cancer targets, but it plans to advance its lead program into Phase 1 testing in 2025. Novo Holdings led Kivu’s Series A financing..

-Kivu Bioscience以9200万美元启动，揭示了抗体-药物偶联物和Lonza子公司Synaffix许可的技术。这家以非洲基伍湖命名的初创公司没有透露其癌症目标，但计划在2025年将其领先项目推进到第一阶段测试。Novo Holdings领导了基伍的A系列融资。。

—Agomab raised $89 million to support ongoing clinical testing of AGMB-129, which is in development as a potential treatment for fibrostenosing Crohn’s disease. In this complication of the inflammatory gut disorder, scar tissue (fibrosis) and inflammation lead to thickening of the bowel. The Antwerp, Belgium-based biotech’s drug is a small molecule designed to block ALK5, a protein involved in a signaling pathway associated with fibrosis.

-Agomab筹集了8900万美元，用于支持正在进行的AGMB-129临床试验，该试验正在开发中，可作为治疗纤维狭窄性克罗恩病的潜在疗法。在这种炎症性肠道疾病的并发症中，疤痕组织（纤维化）和炎症导致肠道增厚。总部位于比利时安特卫普的生物技术公司的药物是一种小分子，旨在阻断ALK5，一种参与与纤维化相关的信号通路的蛋白质。

Agomab’s Series D round added new investors Sanofi and Invus..

Agomab的D轮增加了新的投资者赛诺菲和Invus。。

—Pathos AI raised $62 million as it plans to advance to mid-stage clinical development. P-500, one of two clinical-stage assets the biotech acquired in the past year, is a brain-penetrating small molecule inhibitor of a target called PRMT5. The Chicago-based company says it will use its AI-powered technology to make patient selection and clinical trial design decisions.

-Pathos AI筹集了6200万美元，计划进入中期临床开发阶段。P-500是生物技术公司去年收购的两项临床阶段资产之一，是一种靶向PRMT5的穿透大脑的小分子抑制剂。这家总部位于芝加哥的公司表示，将利用其人工智能技术做出患者选择和临床试验设计决策。

New Enterprise Associates led Pathos AI’s Series C round..

New Enterprise Associates领衔Pathos AI的C系列赛。。

—With a lead drug candidate in Phase 1/2 testing and a new program on its heels, B-cell therapies developer Be Biopharma raised $82 million in Series C financing. The Cambridge-based biotech’s technology engineers B cells to produce therapeutic proteins. Its most advanced program, BE-101, is in development for treating hemophilia B.

-B细胞疗法开发商Be Biopharma在1/2期测试中作为主要候选药物，随后推出了一项新计划，在C系列融资中筹集了8200万美元。总部位于剑桥的生物技术公司的技术工程师B细胞生产治疗性蛋白质。其最先进的项目BE-101正在开发中，用于治疗血友病B。

The next program is BE-102, a potential treatment for hypophosphatasia, a rare inherited disorder that leads to weak bones and teeth. Be Bio last raised money in 2022, a $130 million Series B round..

下一个项目是BE-102，这是一种治疗低磷血症的潜在方法，低磷血症是一种罕见的遗传性疾病，会导致骨骼和牙齿虚弱。Be Bio上次筹集资金是在2022年，这是一轮1.3亿美元的B轮融资。。

Picture: Feodora Chiosea, Getty Images

图片：Feodora Chiosea，Getty Images

Topics

主题

autoimmune disease

自身免疫性疾病

biopharma nl

生物制药

Clinical Trials

临床试验

Investing